Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects

Table 1 Percentage of starting body weight in each treatment group on d 1 and throughout the course of the multiple-dose range-finding study

Day of study	100 mg/kg STAT3 decoy	% SD	67 mg/kg STAT3 decoy	% SD	34 mg/kg STAT3 decoy	% SD	Control (vehicle)	% SD
1.00	100.00	10.93	100.00	13.67	100.00	8.61	100.00	8.89
2.00	97.55	8.82	99.29	13.08	97.81	8.58	97.93	7.66
3.00	100.64	8.05	99.98	12.68	99.49	7.74	100.91	7.31
4.00	103.70	8.57	102.54	11.87	101.28	7.95	101.72	7.00
5.00	104.26	7.83	102.37	12.09	102.15	8.65	100.85	5.96
8.00	105.60	7.47	106.44	12.48	104.78	8.31	105.40	6.71
9.00	106.41	7.90	105.02	12.21	104.75	8.58	103.51	5.51
10.00	104.87	6.93	102.94	12.61	103.91	8.86	102.60	6.60
11.00	106.37	6.96	104.96	12.49	105.00	8.55	103.42	7.01
12.00	105.12	7.17	103.93	12.06	103.64	8.39	103.22	6.24
15.00	109.61	6.81	109.03	11.86	107.53	9.13	106.35	7.09
18.00	111.14	6.98	111.07	12.93	111.18	7.36	109.33	7.52
22.00	112.85	8.04	114.73	15.22	112.32	6.25	111.69	6.47

Data are means ± SD of percentage of starting body weight for each group. Mice were dosed daily for 5 d each week for 2 wks and euthanized on d 22 of the study for clinical chemistry and hematology studies. Mice exhibited no other symptoms except excitability and increased activity. All mice gained body weight over the course of the study. There were no significant differences between the treatment groups or the vehicle control group (p ≥ 0.05, ANOVA or Kruskal-Wallis).

ISSN: 1528-3658